We have previously shown that oxo-4-methylpentanoate promotes islet GABA (γ -aminobutyric acid) metabolism and stimulates insulin secretion. The main aim of this work was to explore the participation of the transamination of branched-chain 2-oxoacids in these processes with the aid of several inhibitors of this enzyme activity. No correlation was found between the transamination of branched-chain 2-oxoacids in islet homogenates and insulin secretion. However, in vivo transamination rates correlated better with the secretion capacity of the different branched-chain 2-oxoacids. Gabapentin, a specific inhibitor of the cytosolic isoenzyme, showed greater potential to decrease the in vitro transamination rates of oxo-3-methylbutyrate and oxo-3-methylpentanoate than those of oxo-4-methylpentanoate and oxohexanoate; this correlated with its capacity to decrease insulin secretion. 4-Methylvaleric acid very strongly inhibited the transamination of all the branched-chain 2-oxoacids and blocked their capacity to decrease islet GABA and to stimulate insulin secretion. KCl at 70 mM at stimulated islet GABA release, subsequently decreasing its tissue concentration. This 'non-metabolic' decrease of GABA suppressed the second phase of insulin secretion triggered by oxo-4-methylpentanoate and oxohexanoate. Oxo-4-methylpentanoate and oxo-3-methylpentanoate suppressed dose-dependent 2-oxoglutarate dehydrogenase activity in islet homogenates. In conclusion, the transamination of branchedchain 2-oxoacids is more important to the stimulation of insulin secretion than their catabolism, and transamination decreases islet GABA concentrations by promoting GABA metabolism. Also, inhibition of 2-oxoglutarate dehydrogenase by branched-chain 2-oxoacids may increase metabolic flux in the 'GABA-shunt' at the expense of reduced tricarboxylic acid cycle flux.
INTRODUCTION
BCKAs (branched-chain 2-oxoacids; also known as branchedchain α-keto acids) trigger a biphasic secretion of insulin in perifused rat islets, which is similar in form to that stimulated by high glucose [1] [2] [3] [4] . Early studies showed that BCKAs were transaminated in a reaction probably catalysed by a specific BCAT (branched-chain amino acid transferase) activity [5] [6] [7] [8] . Moreover, they can be oxidized to CO 2 and an acetoacetate [5, 9, 10] and it has been shown that KIC (oxo-4-methylpentanoate; also known as α-ketoisocaproate) is oxidized at a similar rate to high glucose and its stimulation of insulin secretion might share a common mechanism with the sugar, consisting of an increased catabolic rate [11] . As BCKAs may generate 2OG (2-oxoglutarate) in their transamination reaction with glutamate [8] and hence feed the tricarboxylic acid cycle, their different secretory capacities might also depend on their different rates of transamination. However, this turned out not to be the case, and KIV (oxo-3-methylbutyrate; also known as α-ketoisovalerate), which does not stimulate insulin secretion, showed the maximum rate of transamination in islet homogenates [6] . Since it was found that L-leucine activates GDH (glutamate dehydrogenase) [12] , KIC transamination gained importance as a putative mechanism for increasing energy production and hence insulin release [7] . However, most of the branchedchain α-amino acids (valine, isoleucine, norleucine), except L-leucine, are not GDH-activators, even though some of their corresponding 2-oxocarboxylic acids may trigger a biphasic insulin secretion, such as KMV (oxo-3-methylpentanoate; also known as α-keto-β-methylvaleric acid) or KC (oxohexanoate; also known as α-ketocaproic acid) [8] . It has therefore not yet been settled which is the main metabolic process contributing to the stimulation of insulin secretion by BCKAs in β-cells: their increased catabolism (oxidation), their transamination rate and the generation of 2OG, and/or the stimulation of GDH.
BCAT activity is present as two isoenzymes in the brain: BCAT c , the cytosolic form, predominates in neurons, whereas BCAT m , the mitochondrial form, is more generally expressed in astrocytes and peripheral tissues [13] . Both enzyme activities have been demonstrated in islets of ob/ob mice and no preference for either was found for the BCKA secretagogues KIC or KC [7] . The neuroactive drug gabapentin [1-(aminomethyl) cyclohexaneacetic acid] is a rather specific competitive inhibitor of BCAT c with a K i (0.8-1.4 mmol/l) value similar to the K m for L-leucine, whereas much higher concentrations (65.4 mmol/l) are required to inhibit L-leucine binding to BCAT m [14] . This drug, in combination with others, will be used to characterize the isoenzyme pattern of BCKA transamination in an attempt to explore its relationship with the capacity to stimulate insulin secretion.
KIC has also been found to be capable of significantly reducing intracellular GABA (γ -aminobutyric acid) levels in rat islets [15] . As the rate of GABA release was not modified by KIC and no intracellular accumulation of L-leucine could be demonstrated (it accumulated extracellularly), it was proposed that the 2OG Abbreviations used: BCAT, branched-chain amino acid transferase; BCAT c , cytosolic BCAT; BCAT m , mitochondrial BCAT; BCKA, branched-chain 2-oxoacid; eGABA, ethyl-GABA; GABA, γ-amino butyric acid; gabapentin, 1-(aminomethyl)cyclohexaneacetic acid; GABA-T, GABA transaminase; GDH, glutamic acid dehydrogenase; KC, oxohexanoate; KIC, oxo-4-methylpentanoate; KIV, oxo-3-methylbutyrate; KMV, oxo-3-methylpentanoate; MVA, 4-methylvaleric acid; 2OG, 2-oxoglutarate; 2OGdh, 2OG dehydrogenase; TIU, trypsin inhibitor unit. 1 To whom correspondence should be addressed (email tamarit@med.ucm.es). generated in the transamination reaction might feed GABAtransaminase activity and promote metabolism of the amine in the "GABA-shunt" [15] . BCKAs are known to inhibit the mitochondrial metabolism of 2OG [16] as well as 2OGdh (2OG dehydrogenase) activity [17] . If this could be demonstrated in islet cells, the idea that BCKAs stimulate insulin secretion by increasing GABA-shunt metabolism would be reinforced. Therefore, the aim of this study was to investigate the dependence of BCKA capacity to stimulate insulin secretion and to decrease islet GABA on their rate of transamination using BCAT inhibitors. 
EXPERIMENTAL

Islet insulin secretion
Male Wistar-albino rats (body weight: 250 g) were obtained from the Complutense University colony, housed in cages at 22
• C under a 12 h light/12 h dark cycle and fed ad libitum with a commercial pellet chow. All animal care, use and experimental protocols were submitted and approved by the Ethics Committee of the Complutense University, responsible for the correct application of the order 86/609/CEE (Spanish order 1201/2005). Animals were killed by decapitation and the pancreas dissected out after abdominal laparotomy. The organ was then minced and incubated with collagenase P (Roche Diagnostics, Sant Cugat del Vellès, Spain) in Hanks solution under continuous shaking at 37
• C for several minutes. Insulin secretion was studied in perifused or incubated islets. Two groups, each of 40 rat islets, were perifused in parallel and at a flow rate of 0.5 ml/min with KRBH [Krebs-Ringer (115 mM NaCl, 4.7 mM KCl, 2.56 mM CaCl 2 ·2H 2 O, 1.2 mM KH 2 PO 4 and 1.2 mM MgSO 4 ) buffered with 0.5 mM NaHCO 3 and 20 mM Hepes, supplemented with 0.5 % NEFA (non-esterified fatty acid)-free BSA], and heated at 37
• C. The perifusion pattern was similar in all the experiments. After a pre-perifusion period of 45 min under basal conditions (in the absence of nutrients or at non-stimulatory concentrations of substrates), the perifusion medium was switched to one containing the test substances and maintained for the next 30 min. Finally, the medium was changed back to pre-perifusion conditions where it was maintained for the last 25 min. The perifusate was collected at 1 min intervals during the last 60-70 min of perifusion and its insulin concentration radioimmunologically measured. Alternatively, three batches each of ten islets were incubated in 1 ml of KRBH at 37
• C for 60 min and the concentration of insulin released in the incubation medium was radioimmunologically measured. Pig insulin was radio-iodinated with Na 125 I [18] and rat insulin was used as a standard in the radioimmunoassay of insulin. Insulin antiserum was provided by Dr Janove Sehlin from the Department of Medical Cell Biology at the University of Umeå (Umeå, Sweden).
Islet amino acid extraction
Islet α-amino acids were separated by reverse-phase HPLC after precolumn derivatization with o-phthaldialdehyde [19] and quantified by fluorescence detection. Islets (groups of 20) were incubated for 60 min at 37
• C in 70 μl of the same buffer as that used in perifusions. Incubations were stopped by placing the tubes containing the islets on ice. The medium was aspirated and the islets were washed twice with 100 μl of cold PBS. Finally, 30 μl of 10 % (w/v) 5-sulfosalicylic acid was added in order to extract islet amino acids. Final extracts were kept at − 40
• C until their amino acid content was determined. Twelve amino acids were regularly identified and separated in the extracts and they were measured with a sensitivity close to 1 pmol (aspartate, glutamate, serine, glutamine, histidine, glycine, threonine, arginine, taurine, alanine, tyrosine and GABA). Occasionally, the gradient elution profile of the chromatographic separation was changed in order to also separate and quantify branched-chain α-amino acids (leucine, isoleucine and valine). Islet DNA was measured with a fluorimetric method [20] in an extract of islets that had been previously sonicated (four times, ten strokes at 10 % of the cycle and the minimum potency of a Branson sonifier 450) in 100 μl of 5 mmol/l NaOH. In experiments aimed at investigating the release of amino acids, islets (groups of 30) were incubated for 60 min at 37
• C in 70 μl of the same buffer as that used in perifusions. After stopping the incubation on ice, 50 μl of the supernatant was withdrawn and stored frozen until amino acid measurement was performed. The remaining medium was discarded and the islets were processed as described before for the measurement of their amino acid content.
2OGdh activity assay 2OGdh activity in islet homogenates was studied as the amount of NADH produced at saturating concentrations of 2OG (5 mM) from NAD + (2.5 mM) and measured fluorimetrically in a multiwell plate (Costar assay plate no. 3915; Corning, Corning, NY, U.S.A.) recorder (Varioskan model, Bioanalysis Labsystems S.A., Barcelona, Spain). Isolated islets were homogenized by sonication (four times, ten strokes at 10-20 % of the cycle and the minimum potency of a Branson sonifier 450) in assay buffer (10 mM KH 2 PO 4 and 0.5 mM EDTA, pH 7.2) containing 60 μM leupeptin, 0.0188 TIU (trypsin inhibitor unit)/ml of aprotinin, 2 mM PMSF (in DMSO), 10 mM 2-mercaptoethanol and 0.5 % (v/v) Triton X-100. The islet homogenate was then centrifuged at 4
• C and 42 100 rev./min for 30 min in a 100.Ti rotor of the Optima TM -L-100 XP model ultracentrifuge (Beckman Coulter España S.A.). The enzyme reaction was performed in assay buffer supplemented with 2 mM oxamate, 4 μM rotenone, 0.5 mM coenzyme A, 0.3 mM thiamine pyrophosphate, 2.5 mM dithiothreitol, 0.8 mM CaCl 2 , 1 mM MgCl, 5 mg/ml BSA and the substrates. The enzyme activity was calculated as the slope of the linear increase of NADH fluorescence expressed as the amount of formed product/min per mg of protein by reference to a nucleotide standard curve. The amount of protein was measured in the islet extracts using the method of Lowry et al. [21] and BSA was used as the standard.
BCAT activity assay
BCAT activity was measured in islet homogenates as the amount of the branched-chain α-amino acid (leucine, isoleucine, norleucine or valine) produced at saturating concentrations (1 mM) of the BCKA (KIC, KMV, KC or KIV respectively) and L-glutamate (2 mM). Each branched-chain α-amino acid was isocratically separated by reverse-phase HPLC and fluirometrically detected after its derivatization with ophthaldialdehyde, as described above for the measurements of islet α-amino acids. The reaction was linear for at least 20 min and the amount of α-amino acid accumulated during this time Groups of 40 islets each, pre-perifused without substrates for 45 min, were stimulated for 30 min (between vertical broken lines) with 10 mM of one out of four different BCKA (KIC, KMV, KIV or KC). Pre-perifusion conditions were then re-established during the last 25 min. Each perifusion was repeated a variable number of times (᭹, n = 27 for KIC; , n = 27 for KMV; ᮀ, n = 6 for KC; , n = 6 for KIV). Results are means + − S.E.M.
period was used to calculate enzyme activity. Isolated islets were homogenized by sonication (four times, ten strokes at 10 % of the cycle and the minimum potency of a Branson sonifier 450) in a buffer (50 mM KH 2 PO 4 and 1.0 mM EDTA, pH 7.8) containing 60 μM leupeptin, 0.0188 TIU/ml of aprotinin, 2 mM PMSF (in DMSO), 1.4 mM 2-mercaptoethanol and 0.5 % (v/v) Triton X-100. The islet homogenate was then centrifuged at 4
• C and 42 100 rev./min for 30 min in a 100.Ti rotor of an ultracentrifuge (Optima TM -L-100 XP model). The enzyme reaction was performed in the same buffer supplemented with 50 μM pyridoxal phosphate and the two substrates.
Statistics
All the experimental data are presented here as the means + − S.E.M., and the numbers of separate experiments are given in parentheses. Statistical comparisons were performed with nonpaired, two-tailed Student's t tests.
RESULTS
Effect of BCAT inhibitors on insulin secretion
BCKAs showed different potencies of stimulation of insulin secretion when tested on perifused islets at 10 mM ( Figure 1 ). KIC and KC stimulated a similar, biphasic, secretory response that was slightly higher than that triggered by KMV. KIV only induced a small first phase release and an even lower second phase. In a preliminary screening (at a fixed concentration) of the capacity of different BCAT inhibitors to modify BCKA stimulation of insulin secretion, a greater sensitivity of KMV towards 10 mM DL-α-methyl-leucine (− 35.3 + − 6.8 %, n = 7; P < 0.01) and 5 mM gabapentin (− 60.4 + − 8.8 %, n = 8; P < 0.0004) was observed as compared with KIC, which was not affected at all. In fact, 5 mM gabapentin suppressed by 52 % the second phase of KMV-induced insulin release without modifying the first phase ( Figure 2 ). However, 10 mM MVA (4-methylvaleric acid), an L-leucine structural analogue [13] , was more effective than the other two inhibitors in the suppression of both KMV (− 92.4 + − 1.6 %, n = 8; P < 0.001) and KIC (− 94.7 + − 0.5 %, n = 8; P < 0.001) stimulation of insulin secretion.
As shown in Table 1 , KMV and KIC exhibited a different sensitivity towards gabapentin-induced inhibition of their secretory response: whereas the response triggered by 10 mM KMV was significantly decreased by 10 mM (− 37 %) and 50 mM (− 59 %) gabapentin, 10 mM KIC-stimulation was resistant to 10 mM (− 14 %) and it was suppressed, but to a lower degree, by 50 mM (− 38 %) gabapentin. In batch-type incubations, KIV did not increase insulin secretion above the basal level, but its response was strongly potentiated by 10 mM L-glutamine (Table 1) and this potentiation was dose-dependently decreased by 10 mM (− 57 %) and 50 mM (− 77 %) gabapentin. MVA suppressed very efficiently, and dose-dependently, 10 mM KIC-induced secretion, up to − 90 % at 20 mM (Table 1) .
Islet viability after 30 min (as in the perifusions) exposure to BCAT inhibitors was checked after washing the islets and changing the medium. Pre-treatment of islets with either 10 mM KIC alone or together with 50 mM gabapentin or 20 mM MVA did not modify their subsequent insulin secretory response to 20 mM glucose, or their insulin content (results not shown).
BCKA transamination
BCKA transamination with L-glutamate was measured in islet homogenates by measuring the linear accumulation of the resulting α-amino acid and the effect of a concentration range of different inhibitors investigated. A hierarchy of transamination activities was observed among the different BCKAs assayed: the highest was obtained with KIV, followed in decreasing order by KIC, KMV and KC (Table 2) . KIV and KMV transaminations were more sensitive to the inhibitory effect of gabapentin than those of KIC and KC, whereas transamination of KIV and KMV were significantly decreased by 2 and 10 mM gabapentin; the inhibitor did not modify the transamination of the latter two. Moreover, 50 mM gabapentin caused a greater suppression of transamination with KIV (− 85.5 %) and KMV (− 78.3 %) than with either KIC (− 61.0 %) or KC (− 55.6 %). MVA behaved as a potent inhibitor of BCKA transamination (over 87 % at 20 mM) and did not show any preference for a particular BCKA (Table 2) . DL-α-Methyl-leucine suppressed 10 mM KIC transamination at 10 and 20 mM by 33.0 and 43.5 % respectively (Table 2 ). Groups of 40 islets each, pre-perifused without substrates for 45 min, were stimulated for 30 min (between vertical broken lines) with 10 mM KMV without ( , n = 27) or with ( , n = 6) 5 mM gabapentin. Pre-perifusion conditions were then re-established during the last 25 min. Results are means + − S.E.M.
Table 1 Effect of two inhibitors of BCKA transamination activity (gabapentin and μVA) on islet insulin secretion stimulated by several 2-oxoacids
Three groups, each of ten islets, were incubated at 37 • C for 1 h in 1 ml of KRBH. The insulin accumulated in the incubation medium was radioimmunologically measured (IRI). N.S., not significant.
IRI (pmol insulin/min per islet)
10 mM KIC n P 10 mM KMV n P 10 mM KIV plus 10 mM L-glutamine n P Isolated islets were sonicated in a lysis buffer as described in the Experimental section. The enzymatic reaction was measured as the amount of branched-chain α-amino acids (leucine, isoleucine, valine or norleucine) linearly accumulated at saturating concentrations of the corresponding 2-oxoacid (KIC, KMV, KIV or KC) and L-glutamate (1 and 2 mM respectively). The α-amino acids were quantified by their fluorescence after being derivatized with o-phthaldialdehyde and separated by reverse-phase HPLC. N.S., not significant. BCKA transamination activity was also measured in intact islets preloaded for 1 h with different L-glutamine concentrations (0, 0.5 and 10.0 mM); the quantity of α-amino acids, either released or remaining in the islets, was measured after washing the islets (to rid them of glutamine) and incubating them for a second hour in the presence of a 10 mM concentration of the different BCKAs. No significant accumulation of any of the branched chain α-amino acids (leucine, isoleucine or valine) could be detected in the islets at any L-glutamine concentration (results not shown). As shown in Table 3 , the amount of the branched-chain α-amino acid released (in vivo transamination) increased with the concentration of L-glutamine to which islets were pre-exposed during the first hour. In the absence of L-glutamine, the production of leucine was significantly greater than that of isoleucine, but this difference disappeared at either 0.5 or 10.0 mM L-glutamine. By contrast, the amount of valine released was consistently lower than that of leucine at all L-glutamine concentrations tested (Table 3) . Both KMV and KIV significantly increased the islet content of aspartate and glutamate with respect to the control and also in comparison with KIC (Table 3) . KIC was the only BCKA that significantly decreased islet GABA content in the absence of L-glutamine (Table 3) . However, at a L-glutamine concentration close to the physiological plasma concentration (0.5 mM) or higher (10 mM), all three BCKAs significantly diminished the islet GABA content.
In order to check the hypothesis that BCKA transamination is responsible for increased GABA metabolism and therefore for the stimulation of insulin secretion, we investigated whether the inhibition of transamination would also block the reduction of islet GABA. For that purpose, MVA was used as the BCAT inhibitor because it suppressed with similar efficiency KIC-induced insulin secretion and the rate of 2-oxoacid transamination to leucine in islet homogenates. The effect of MVA, measured with the same experimental design used to evaluate in vivo transamination (see preceding paragraph), was tested on islets that had been pre-loaded for 1 h with 10 mM L-glutamine. MVA (10 mM 
Effect of the intracellular GABA concentration on insulin secretion
The islet GABA content is dose-dependently increased by the extracellular L-glutamine concentration and reaches close to the maximum level at the physiological plasma concentration of the α-amino acid (0.5 to 1.0 mM) [22] . We have shown before [15] , and corroborated in the present study (Table 3) , that KIC efficiently reduces the islet content of GABA at any L-glutamine concentration. This effect was ascribed to 2OG generation in the transamination of KIC to leucine and the subsequent GABA transamination with the generated 2OG. We showed above that increasing the intracellular GABA concentration at two different levels with eGABA (1.5 and 5.0 mM) did not modify the rate of KIC transamination measured as the release of leucine. This apparently suggests that the observed suppression of intracellular GABA does not limit the rate of KIC transamination but perhaps restricts GABA transamination. We therefore explored whether the secretory response to KIC might be improved by increasing intracellular GABA levels with the membrane-permeable analogue. As shown in Figure 3(A) , the simultaneous perifusion of rat islets with 10 mM KIC together with 1 mM eGABA did not modify the first phase of insulin secretion but strongly decreased the sustained, second phase of insulin release by more than 50 % (16.2 + − 3.0, n = 4, compared with 33.5 + − 3.0 ng of insulin/20 min; 40 islets, n = 6, P < 0.005). A further increase of intracellular GABA with 5 mM eGABA decreased slightly more (− 77 %) the second phase of KICinduced insulin secretion (5.4 + − 1.4, n = 5, compared with 23.3 + − 4.4 ng of insulin/20 min; 40 islets, n = 4; P < 0.002), but did not modify first phase release (results not shown). The second phase of the secretory response to 10 mM KMV was similarly decreased by 5 mM eGABA by 86 % (4.5 + − 1.7, n = 6, compared with 32.0 + − 5.3 ng of insulin/20 min; 40 islets, n = 4; P < 0.0004) ( Figure 3B ). These results suggest that islet GABA, besides being a potential metabolic substrate, might have other effects on the mechanism of insulin secretion above certain concentrations.
Preliminary results have shown that 5 mM eGABA significantly decreases glucose-induced insulin secretion and this effect correlated with a hyperpolarization of the β-cell plasma membrane [23] . Therefore, we tried to counteract eGABA-induced decrease of the secretory response to KIC by depolarizing the islets with 70 mM KCl: surprisingly, depolarization itself suppressed the second phase of release by 61 % (8.8 + − 0.8, n = 27, compared with 22.6 + − 1.7 ng of insulin/20 min; 40 islets, n = 27; P < 0.0001) (Figure 4) , whereas it had no effect on glucose (20 mM) stimulation (results not shown). The addition of 1, 5 or 10 mM eGABA did not modify depolarization-induced suppression of the second phase of release triggered by 10 mM Table 4 Effect of 70 mM KCl depolarization and/or 10 mM KIC on islet content and release of α-amino acids Three groups each of 30 islets were pre-incubated for 1 h (a) with 10 mM L-glutamine. After washing the islets twice with saline, in order to remove L-glutamine, which would otherwise contaminate HPLC separation, they were further incubated for a second hour (b) with 10 mM KIC. α-Amino acids were quantified in islets and incubation medium by their emitted fluorescence after being derivatized with o-phthaldialdehyde and separated by reverse phase HPLC. The numbers in parentheses represent the number of experiments; N.S., not significant. suppressed by 63 % the second phase of secretion triggered by 10 mM KC (9.9 + − 1.3, n = 6, compared with 27.2 + − 0.8 ng of insulin/20 min; 40 islets, n = 5; P < 0.0001) ( Figure 5B ). As we have hypothesized [15] that KIC stimulation of insulin secretion is at least partially dependent on the promotion of GABA metabolism, we checked whether the decrease of the K + electrochemical potential by 70 mM KCl might interfere with the availability of GABA in the islets. For that purpose, islets were pre-loaded with 10 mM L-glutamine for 1 h and, after washing the remaining extracellular glutamine, both islet content and the release of α-amino acids were measured after a second hour of incubation in the presence of 70 mM KCl. Table 4 shows that, under this depolarizing condition, the release of GABA and taurine were increased by more than 100 % and this increment was not affected by the simultaneous presence of 10 mM KIC. There were corresponding decreases of both GABA and taurine contained within the cell (− 32 % and − 40 % respectively). It was shown again that 10 mM KIC alone decreased by 42 % islet GABA content without modifying taurine content. KIC was even capable of suppressing further GABA (P < 0.008), but not taurine, islet content in the presence of 70 mM KCl.
Modification of 2OGdh activity by BCKAs in islet homogenates
2OGdh enzymatic activity competes for its substrate with GABA transaminase, the enzyme that initiates metabolism in the GABAshunt. The confirmation in islet homogenates that 2OGdh activity is inhibited by BCKAs, as has been demonstrated in other tissues [16, 17] , would strengthen the importance of an increased GABA-shunt metabolism in the stimulation of insulin secretion by KIC. As shown in Table 5 , KIC decreased 2OGdh activity in islet homogenates in a dose-responsive manner between 1 and 10 mmol/l. At 10 mM, KIC decreased the enzyme activity to approx. 6 % of the control. Similar effects were found in homogenates of rat cerebellum (results not shown). KMV (5 mM) induced a stronger reduction of 2OGdh activity than 5 mM KIC in both islets and cerebellum: it almost abolished the enzymatic activity in islet homogenates (results not shown). 
DISCUSSION
It has been shown recently that the secretory response to KIC in incubated mouse islets was inhibited by DL-α-methyl-leucine in a concentration-dependent manner, although the drug's effect on islet transamination was not checked [24] . We have demonstrated in the present paper that DL-α-methyl-leucine inhibited KIC transamination in rat islet homogenates in a concentration-sensitive manner, but that it did not suppress KICinduced stimulation of insulin secretion. This different sensitivity to DL-methyl-leucine between mouse [24] and rat islets might be attributed to the species differences. Gabapentin is a wellcharacterized and specific inhibitor of BCAT c , which is known to predominate in neurons [13] . Therefore it was used in the present study as a tool to uncover specific differences in the affinity among the different BCKAs for the transaminase isoforms.
The results from the present study confirm previous studies indicating that both BCAT c and BCAT m activities are present in rat islets [7] . The study of the effect of a range of gabapentin concentrations on BCKA transamination in islet homogenates allows us to conclude that both KIC and KC, at variance with KMV and KIV, have a higher affinity for the mitochondrial than the cytosolic isoform. The existence of a mitochondrial activity might facilitate the concatenation of 2-oxoacid transaminase and GABA transaminase activities when islets are exposed to KIC and KC ( Figure 6 ). This would result in a greater efficiency of KIC and KC to reduce intracellular GABA compared with KMV and KIV, which are preferentially transaminated by the cytosolic isoenzyme. This was confirmed for KIC in the present study.
In previous experiments in our laboratory, it was found that KC induced a greater decrease of islet GABA (− 53 %) than KMV (− 32 %) in the absence of glutamine (results not shown). The weak capacity of KIV to decrease intracellular GABA correlates with its low secretory competence and is in apparent contradiction to its high rate of transamination in islet homogenates. The rank of transamination activities found in the present study (KIV>KIC>KMV>KC) confirms previously published results [6] in rat islets and emphasizes the lack of correlation between transamination rate and secretory strength. However, when tested in vivo, KIV conversion into valine was much lower than synthesis and release of leucine from KIC under all glutamine concentrations studied; KMV transamination to isoleucine was also lower than leucine formation from KIC. These differences in transamination rates may be, at least partially, determined by differences in transport rates through the plasma membrane of β-cells. They correlate better than in vitro transamination rates with the secretory potency of the different BCKAs and their capacity to decrease islet GABA. In conclusion, See text for further details. CIT, citrate; FUM, fumarate; GAD, glutamic acid decarboxylase; GHB, γ -hydroxibutyrate; ISOCIT, isocitrate; MAL, malate; MDH, malate dehydrogenase (malic enzyme); OxAc, oxaloacetate; PYR, pyruvate; SSA-dh, semialdehyde succinic acid dehydrogenase; SSA-R, semialdehyde succinic acid reductase; SUCC, succinate.
the importance of BCKA transamination in their mechanism of stimulation of insulin secretion now seems to be settled. As a corollary, BCKA oxidation does not seem to contribute much to the stimulation of secretion, as pointed out by Rabaglia et al. [24] . Moreover, it has been shown that KIC by itself is not a good substrate in isolated mitochondria but it increases ATP production in combination with L-glutamate [25] . This supports our finding that KIC is mainly transaminated by BCAT m in islet cells.
If BCKA oxidation is not important, what would then be the source of metabolic energy used to initiate and maintain insulin secretion? A 'non-metabolic' decrease of islet GABA induced by its increased release after high K + (70 mM KCl) depolarization (Table 4) significantly suppressed the second phase of insulin secretion stimulated by KIC and KC without affecting the first one. It is plausible that the increased GABA release might restrict the availability of the amine to feed the GABA-shunt, and this would in turn diminish the rate of ATP generation necessary to maintain sustained secretion. In support of this interpretation, it has recently been shown that islets of SUR1 knockout mice, which are permanently depolarized, exhibit a diminished metabolic flow in the GABA-shunt [26] . Therefore, it seems that GABA is the main metabolic fuel used during the stimulation of insulin secretion by BCKAs. Another argument in support of this idea is that BCKAs block 2OGdh in the tricarboxylic acid cycle, favouring metabolism in the GABA-shunt ( Figure 6 ). In contrast, first phase release in response to KIC might be more dependent on a direct effect of the 2-oxoacids on K + ATP channels at the sulfonylureabinding site that would close the channels irrespective of the ATP concentration [27, 28] .
At variance with KIC and KC, KMV-induced secretion was not significantly modified by K + -depolarization. The latter, as well as KIV, are predominantly transaminated by BCAT c and the 2OG formed might be less efficiently transported into mitochondria to serve as a susbstrate of GABA-T (GABA transaminase) (see Figure 6 ). Both KMV and KIV may be substantially metabolized to succinic acid as reflected by the increased synthesis of aspartate, which probably arises from transamination of oxaloacetate. The stimulation of insulin secretion by KMV is perhaps more dependent on its partial catabolism in the citric acid cycle than either KIC or KC.
eGABA did not improve KIC transamination or, as expected, KIC-induced insulin secretion. Neither did it rescue the stimulation of insulin secretion by KIC after depleting islet GABA content with 70 mM KCl. These results cast some doubt on the suitability of eGABA as a true analogue of GABA, a matter that is presently under investigation.
In summary, BCKA stimulation of insulin secretion depends on their transamination rates with glutamate that generates 2OG. As 2OGdh is inhibited by BCKAs in the form of KIC, 2OG is used preferentially by GABA transaminase, resulting in an increased metabolic flux in the GABA-shunt and a decreased intracellular GABA level ( Figure 6 ). The increased GABA metabolism would contribute to the maintenance of high ATP generation, as required for sustained insulin secretion.
